Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSXILZ)

Drug Name
Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275 Drug Info
Synonyms CHEMBL386023; Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44388129
TTD Drug ID
DMSXILZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Somatostatin receptor type 3 (SSTR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [2]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [3]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [4]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [5]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [1]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [3]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [4]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [3]
Cytotoxin Peptide Conjugate DM7SVLZ Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Somatostatin receptor type 1 (SSTR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pasireotide DMHM7JS Cushing disease 5A70 Approved [8]
Lutetium Lu 177 dotatate DMN1XVC Neuroendocrine cancer 2B72.1 Approved [9]
ODT-8 DMBWO5T N. A. N. A. Phase 3 [3]
FR-121196 DMNRUGA Alzheimer disease 8A20 Terminated [4]
SOMATOSTATIN DMIOFQE Acromegaly 5A60.0 Investigative [5]
Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V Discovery agent N.A. Investigative [1]
Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE Discovery agent N.A. Investigative [3]
SRIF-28 DM0OM9L Discovery agent N.A. Investigative [6]
99mTc-MIP-1407 DMYPD5L Neuroendocrine cancer 2B72.1 Investigative [4]
Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor type 1 (SSTR1) TTIND6G SSR1_HUMAN Inhibitor [1]
Somatostatin receptor type 3 (SSTR3) TTJX3UE SSR3_HUMAN Inhibitor [1]

References

1 Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
3 Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52.
6 Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97.
7 An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
9 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.